NEW YORK, May 12 (GenomeWeb News) - ParAllele BioScience has started a pharmacogenomics collaboration with Merck, and has given the National Cancer Institute early access to its SNP genotyping platform, the company said today.
Under the agreement with Merck, South San Francisco-based ParAllele will determine genetic variations in a number of genes chosen by Merck using its SNP genotyping platform. Merck will fund the study, which is the second collaboration between the companies.
ParAllele's MegAllele SNP genotyping platform will also be used by the Laboratory of Genomic Diversity at NCI-Frederick, an early access customer. The technology does not require the DNA around each SNP to be amplified prior to analysis, according to the company.